3、2023年9月21日互动易回复：公司为欧美生物创新药公司提供阿尔茨海默相关中间体服务。 4、2025年7月9日互动易，公司现有氟化生产能力包括特殊氟化剂氟化（如四氟化硫、氟化氢吡啶、氟 化氢三乙胺）、氟化氢氟化、氟化钾氟化等。 来源：新浪证券-红岸工作室 2月27日，金凯生科跌1.85%，成交额1.40亿元，换手率6.30%，总市值47.24亿元。 异动分析 CRO概念+减肥药+阿尔茨海默概念+氟化工概念+人民币贬值受益 1、公司的主营业务是为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定 制研发生产服务。公司的主要产品是含氟类CDMO业务、非含氟类CDMO业务。 2、2023年8月8日互动易回复：公司上市的募投项目"医药中间体项目"和"年产 190 吨高端医药产品项目 包含司美格鲁肽（Semaglutide）口服制剂小分子吸收增强剂 SNAC 的中间体。 区间今日近3日近5日近10日近20日主力净流入-1575.73万-2528.60万-2748.99万-9459.02万-1.06亿 5、根据2024年年报，公司海外营收占比为61.18%，受益于人民币贬值。 (免责声明：分析内容来 ...

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main products of the company include fluorinated CDMO services and non-fluorinated CDMO services [2]. - The company has a significant project involving the production of intermediates for Semaglutide oral formulations, which is part of its fundraising projects [2][3]. - As of the 2024 annual report, overseas revenue accounted for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a remarkable year-on-year increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On February 12, the company's stock price decreased by 0.21%, with a trading volume of 93.35 million yuan and a turnover rate of 4.24%, resulting in a total market capitalization of 4.659 billion yuan [1]. - The stock has seen a net outflow of 4.177 million yuan from major investors today, with a ranking of 31 out of 52 in its industry [5][6].

- The report introduces a "Total Heat Indicator" for monitoring market sentiment, which aggregates the heat indicators of individual stocks within broad-based indices, industries, and concepts[10][11] - The "Total Heat Indicator" is defined as the sum of the browsing, self-selection, and click counts of a stock, normalized by its market share on the same day, and then multiplied by 10,000, with a value range of [0,10000][10] - The report constructs a simple rotation strategy based on the weekly heat change rate (MA2) of broad-based indices, buying the index with the highest heat change rate at the end of each week, and staying out of the market if the "Others" group has the highest change rate[16][18] - The rotation strategy based on the heat change rate (MA2) of broad-based indices has an annualized return of 8.74% since 2017, with a maximum drawdown of 23.5%, and a return of 2.1% in 2026[19] - The report also constructs two simple portfolios based on the heat change rate of concepts, selecting the top 10 and bottom 10 stocks by total heat within the top 5 concepts with the highest heat change rate each week, and holding them equally[35] - The "BOTTOM" portfolio of low-heat stocks within high-heat concepts has historically achieved an annualized return of 15.71% with a maximum drawdown of 28.89%[37]

Strong Stocks - As of January 13, the Shanghai Composite Index fell by 0.64% to 4138.76 points, the Shenzhen Component Index decreased by 1.37% to 14169.4 points, and the ChiNext Index dropped by 1.96% to 3321.89 points [1] - A total of 75 stocks in the A-share market hit the daily limit, with the top three strong stocks being: Luxin Venture Capital (600783), Hangxiao Steel Structure (600477), and Julong Cable (002342) [1] - Detailed data for the top 10 strong stocks includes: - Luxin Venture Capital (600783): 13 days with 11 limit-ups, turnover rate of 20.18%, and closing price of 54.9 - Hangxiao Steel Structure (600477): 4 consecutive limit-ups, turnover rate of 15.79%, and closing price of 16.3 - Julong Cable (002342): 4 consecutive limit-ups, turnover rate of 39.34%, and closing price of 48.2 [1] Strong Concept Sectors - The top three concept sectors with the highest gains in the A-share market are: AI Applications, CRO Concept, and Cell Immunotherapy [2] - Detailed data for the top 10 concept sectors includes: - AI Applications: increased by 10.3% - CRO Concept: increased by 3.56% - Cell Immunotherapy: increased by 2.92% [3]

Core Viewpoint - The company JinKai Life Science has shown significant growth in revenue and profit, driven by its CDMO services for pharmaceutical companies and benefiting from the depreciation of the RMB [4][8]. Group 1: Company Overview - JinKai Life Science Co., Ltd. is located in Fuxin City, Liaoning Province, and was established on June 8, 2009, with its IPO on August 3, 2023 [8]. - The company specializes in providing custom development and manufacturing services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies [2][8]. - The main revenue sources include 98.36% from product sales, 0.90% from technical services, 0.67% from trade services, and 0.07% from other sources [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96% [8]. - The net profit attributable to the parent company was 103 million yuan, showing a remarkable year-on-year increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 61.18% of total revenue [4]. - The company is involved in various concepts including CRO, weight loss drugs, Alzheimer's-related services, and fluorochemical products [2][3]. - The stock has seen a recent increase in trading volume and interest, with a significant net inflow of 8.75 million yuan on the latest trading day [5][6].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Business Overview - The main business involves offering small molecule CDMO services to global life science clients, assisting in the synthesis process of innovative drug development [8]. - The company's revenue composition includes 98.36% from product sales, 0.90% from technical services, 0.67% from trade services, and 0.07% from other sources [8]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to the parent company of 103 million yuan, reflecting a significant increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Market Position - As of December 19, the number of shareholders in the company was 14,300, a decrease of 0.54% from the previous period, while the average circulating shares per person increased by 0.54% to 3,974 shares [8]. - The company benefits from a 61.18% overseas revenue share, aided by the depreciation of the Chinese yuan [4]. Product and Service Development - The company is involved in the development of intermediates for drugs related to Alzheimer's disease and has capabilities in producing specialized fluorinated agents [3][4]. - The company’s listed fundraising projects include the "Pharmaceutical Intermediate Project" and a project for producing 190 tons of high-end pharmaceutical products, which includes intermediates for Semaglutide oral formulations [2][3].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for globally recognized pharmaceutical companies [2][8]. - The company has a significant focus on fluorinated CDMO services, including specialized fluorination agents and other fluorinated products [3][8]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to the parent company of 103 million yuan, reflecting a substantial increase of 163.24% [8]. - The company has distributed a total of 117 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On December 16, the company's stock price fell by 2.50%, with a trading volume of 39.89 million yuan and a turnover rate of 2.15%, resulting in a total market capitalization of 3.896 billion yuan [1]. - The stock has shown no clear trend in major capital inflows, with a net outflow of 4.2829 million yuan today, ranking 27th out of 52 in its industry [5][6].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for well-known pharmaceutical companies globally [2][8]. - The company has a significant focus on fluorinated CDMO services, including specialized fluorination agents and other fluorinated products [3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a remarkable year-on-year increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On December 15, the company's stock price decreased by 0.54%, with a trading volume of 30.35 million yuan and a turnover rate of 1.61%, resulting in a total market capitalization of 3.996 billion yuan [1]. - The stock has seen a net inflow of 861,200 yuan from major investors today, with a ranking of 10 out of 52 in its industry, indicating a slight increase in major investor positions over the past two days [5][6].

Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for globally recognized pharmaceutical companies [2][8]. - The company has a significant focus on fluorinated CDMO services, including special fluorinated agents and various fluorination processes [3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the Renminbi [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved operating revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a year-on-year increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On December 10, the company's stock price decreased by 1.01%, with a trading volume of 33.1865 million yuan and a turnover rate of 1.75%, resulting in a total market capitalization of 4.019 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 2.4753 million yuan today, indicating a lack of clear control by major investors [5][6].

来源：新浪证券-红岸工作室 12月4日，金凯生科跌0.75%，成交额3249.27万元，换手率1.72%，总市值39.90亿元。 异动分析 CRO概念+减肥药+阿尔茨海默概念+氟化工概念+人民币贬值受益 1、公司的主营业务是为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定 制研发生产服务。公司的主要产品是含氟类CDMO业务、非含氟类CDMO业务。 2、2023年8月8日互动易回复：公司上市的募投项目"医药中间体项目"和"年产 190 吨高端医药产品项目 包含司美格鲁肽（Semaglutide）口服制剂小分子吸收增强剂 SNAC 的中间体。 3、2023年9月21日互动易回复：公司为欧美生物创新药公司提供阿尔茨海默相关中间体服务。 4、2025年7月9日互动易，公司现有氟化生产能力包括特殊氟化剂氟化（如四氟化硫、氟化氢吡啶、氟 化氢三乙胺）、氟化氢氟化、氟化钾氟化等。 5、根据2024年年报，公司海外营收占比为61.18%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-346.97万，占比0.11%，行业排名 ...